42.JPG)
Global Orphan Drugs Market Size is valued at USD 213.6 Billion in 2024 and is predicted to reach USD 669.5 Billion by the year 2034 at a 12.2% CAGR during the forecast period for 2025-2034.
Orphan drugs market are recognized as the potential therapeutic market because diseases which are covered under the market are life-threatening diseases to treat disease which are very rare. More often rare diseases are genetic and present throughout a person’s entire life, even though symptoms may not immediately appear.
The prevalence of patients suffering from rare disorders is less, for instance, According to the survey carried out by QuintilesIMS Institute, only 6,084 rare diseases were reported in the US in 2016, because of this many pharmaceutical industries do not entertain the manufacturing of orphan drugs. Thus, less adoption rate of these drugs restrains the market. However, the various financial and legal incentive provided by the governments and technological advancement expected to fuel the growth of market near the future.
The Global Orphan Drugs market is segmented on the basis of drug type, top selling drug and therapy area. Based on the drug type, the market is divided into biological, non-biological. On the basis of top selling drug, the market is segmented into revlimid, rituxan, copaxone, opdivo, keytruda, imbruvica, avonex, sensipar, soliris and other top selling drugs. based on the therapeutic area, the market is divided into oncology, blood, central nervous system, endocrine, cardiovascular, respiratory, immunomodulatory and other disease types. Based on region, the market is studied across North America, Asia-Pacific, Europe, and LAMEA. Among that Europe held the largest share of the market, followed by America and Asia Pacific. On the other hand, North America is expected to dominate the market during the analysis of forecast period.
|
Report Attribute |
Specifications |
|
Market Size Value In 2024 |
USD 213.6 Billion |
|
Revenue Forecast In 2034 |
USD 669.5 Billion |
|
Growth Rate CAGR |
CAGR of 12.2% from 2025 to 2034 |
|
Quantitative Units |
Representation of revenue in US$ Bn,and CAGR from 2025 to 2034 |
|
Historic Year |
2021 to 2024 |
|
Forecast Year |
2025-2034 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Drug Type, By Top Selling Drugs, By Therapy Area |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico ;The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia |
|
Competitive Landscape |
Bristol-Myers Squibb Company, Celgene Corporation, F. Hoffmann-La Roche Ltd, Amgen, Biogen, Bayer, Novartis AG, GlaxoSmithKline plc, Johnson & Johnson, AbbVie Inc, Eli Lilly and Company, Alexion, Pharmaceuticals, Shire, Novo Nordisk, AstraZeneca, Eisai, Daiichi Sankyo, Merck, Teva, Pharmaceutical Industries, Actelion Pharmaceuticals Ltd., Aegerion Pharmaceuticals Players among others. |
|
Customization Scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Orphan Drugs Market Snapshot
Chapter 4. Global Orphan Drugs Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Industry Analysis – Porter’s Five Forces Analysis
4.6. Competitive Landscape & Market Share Analysis
4.7. Clinical Trial/Pipeline Analysis Snapshot
4.8. COVID 19 Impact on Pharmaceutical Industry
Chapter 5. Market Segmentation 1: Drug Types Estimates & Trend Analysis
5.1. Drug Types & Market Share, 2024 & 2034
5.2. Market Size (Value) & Forecasts and Trend Analyses, 2021 to 2034 for the following Drug Types:
5.2.1. Biological
5.2.2. Non-Biological
Chapter 6. Market Segmentation 2: Top Selling Drugs & Trend Analysis
6.1. Top Selling Drugs & Market Share, 2024 & 2034
6.2. Market Size (Value)& Forecasts and Trend Analyses, 2021 to 2034 for the following Top Selling Drugs:
6.2.1. Revlimid
6.2.2. Rituxan
6.2.3. Copaxone
6.2.4. Opdivo
6.2.5. Keytruda
6.2.6. Imbruvica
6.2.7. Avonex
6.2.8. Sensipar
6.2.9. Soliris
6.2.10. Other Top Selling Drugs
Chapter 7. Market Segmentation 3: Therapy Area & Trend Analysis
7.1. Therapy Area & Market Share, 2024 & 2034
7.2. Market Size (Value)& Forecasts and Trend Analyses, 2021 to 2034 for the following Therapy Area
7.2.1. Oncology
7.2.2. Blood
7.2.3. Central Nervous System
7.2.4. Endocrine
7.2.5. Cardiovascular
7.2.6. Respiratory
7.2.7. Immunomodulatory
7.2.8. Other Disease Types
Chapter 8. Orphan Drugs Market Segmentation 4: Regional Estimates & Trend Analysis
8.1. North America
8.1.1. North America Orphan Drugs Market revenue (US$ Million) estimates and forecasts Drug Types, 2021-2034
8.1.2. North America Orphan Drugs Market revenue (US$ Million) estimates and forecasts by Top Selling Drugs, 2021-2034
8.1.3. North America Orphan Drugs Market revenue (US$ Million) estimates and forecasts Therapy Area, 2021-2034
8.1.4. North America Orphan Drugs Market revenue (US$ Million) estimates and forecasts by country, 2021-2034
8.1.4.1. U.S.
8.1.4.2. Canada
8.2. Europe
8.2.1. Europe Orphan Drugs Market revenue (US$ Million) estimates and forecasts by Drug Types, 2021-2034
8.2.2. Europe Orphan Drugs Market revenue (US$ Million) estimates and forecasts by Top Selling Drugs, 2021-2034
8.2.3. Europe Orphan Drugs Market revenue (US$ Million) estimates and forecasts Therapy Area, 2021-2034
8.2.4. Europe Orphan Drugs Market revenue (US$ Million) by country, 2021-2034
8.2.4.1. Germany
8.2.4.2. Poland
8.2.4.3. France
8.2.4.4. Italy
8.2.4.5. Spain
8.2.4.6. UK
8.2.4.7. Rest of Europe
8.3. Asia Pacific
8.3.1. Asia Pacific Orphan Drugs Market revenue (US$ Million) Drug Types, 2021-2034
8.3.2. Asia Pacific Orphan Drugs Market revenue (US$ Million) estimates and forecasts by Top Selling Drugs, 2021-2034
8.3.3. Asia Pacific Orphan Drugs Market revenue (US$ Million) estimates and forecasts Therapy Area, 2021-2034
8.3.4. Asia Pacific Orphan Drugs Market revenue (US$ Million) by country, 2021-2034
8.3.4.1. China
8.3.4.2. India
8.3.4.3. Japan
8.3.4.4. Australia
8.3.4.5. Rest of Asia Pacific
8.4. Latin America
8.4.1. Latin America Orphan Drugs Market revenue (US$ Million) Drug Types, 2021-2034
8.4.2. Latin America Orphan Drugs Market revenue (US$ Million) estimates and forecasts by Top Selling Drugs, 2021-2034
8.4.3. Latin America Orphan Drugs Market revenue (US$ Million) estimates and forecasts Therapy Area, 2021-2034
8.4.4. Latin America Orphan Drugs Market revenue (US$ Million) by country, 2021-2034
8.4.4.1. Brazil
8.4.4.2. Rest of Latin America
8.5. MEA
8.5.1. MEA Orphan Drugs Market revenue (US$ Million) estimates and forecasts Drug Types, 2021-2034
8.5.2. MEA Orphan Drugs Market revenue (US$ Million) estimates and forecasts by Top Selling Drugs, 2021-2034
8.5.3. MEA Orphan Drugs Market revenue (US$ Million) estimates and forecasts Therapy Area, 2021-2034
8.5.4. MEA revenue Orphan Drugs Market revenue (US$ Million) by country, (US$ Million) 2021-2034
8.5.4.1. South Africa
8.5.4.2. Rest of MEA
Chapter 9. Competitive Landscape
9.1. Major Mergers and Acquisitions/Strategic Alliances
9.2. Company Profiles
9.2.1. Bristol-Myers Squibb Company
9.2.2. Celgene Corporation
9.2.3. F. Hoffmann-La Roche Ltd
9.2.4. Amgen
9.2.5. Biogen
9.2.6. Bayer
9.2.7. Novartis AG
9.2.8. GlaxoSmithKline plc
9.2.9. Johnson & Johnson
9.2.10. AbbVie Inc
9.2.11. Eli Lilly and Company
9.2.12. Alexion Pharmaceuticals
9.2.13. Shire
9.2.14. Novo Nordisk
9.2.15. AstraZeneca
9.2.16. Eisai
9.2.17. Daiichi Sankyo
9.2.18. Merck
9.2.19. Teva Pharmaceutical Industries
9.2.20. Actelion Pharmaceuticals Ltd.
9.2.21. Aegerion Pharmaceuticals
Other Prominent Players
Global Orphan Drugs Market Revenue by Drug Types
Global Orphan Drugs Market Revenue Based on Top Selling Drugs
Global Orphan Drugs Market Revenue Based on Therapy Area
Global Orphan Drugs Market Revenue Based on Region
Europe Orphan Drugs Market Revenue by Country
North America Orphan Drugs Market Revenue by Country
Asia Pacific Orphan Drugs Market Revenue by Country
Latin America Orphan Drugs Market Revenue by Country
Middle East & Africa Orphan Drugs Market Revenue by Country
InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.
Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.
Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.
Secondary research
The secondary research sources that are typically mentioned to include, but are not limited to:
The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista
Primary Research:
Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies
The contributors who typically take part in such a course include, but are not limited to:
Data Modeling and Analysis:
In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.
The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.
To know more about the research methodology used for this study, kindly contact us/click here.
